Andrew Littlehale
Geen lopende functies
Profiel
Mr. Andrew Littlehale is Vice President-Finance at FORMA Therapeutics, Inc.
Mr. Littlehale was previously employed as Controller by Genomics Collaborative, Inc., Finance Director by SeraCare Life Sciences, Inc., and Senior Director-Finance & Administration by Aeris Therapeutics LLC.
He received his undergraduate degree from Wheaton College (Illinois) and an MBA from Suffolk University.
Eerdere bekende functies van Andrew Littlehale
Bedrijven | Functie | Einde |
---|---|---|
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Financieel Directeur/CFO | - |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Corporate Officer/Principal | - |
SeraCare Life Sciences, Inc.
SeraCare Life Sciences, Inc. Medical SpecialtiesHealth Technology SeraCare Life Sciences, Inc. provides in vitro diagnostics and clinical laboratory products. It supplies diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers. The firm’s products include Next-Gen Sequencing and Digital PCR Tools, Controls and Reference Materials, Validation and Lot Qualification Materials, Plasma and Serum Diluents/Derivatives, Cell Culture Reagents, KPL Antibodies and Conjugates and KPL Immunoassay Reagents and Kits. The company was founded in 1984 and is headquartered in Milford, MA. | Financieel Directeur/CFO | - |
Genomics Collaborative, Inc.
Genomics Collaborative, Inc. Medical SpecialtiesHealth Technology Genomics Collaborative, Inc. provides clinical samples and applies human genetics to target validation for drug discovery. The company is based in Cambridge, MA. The company was founded by Phyllis I. Gardner and Edward E. Harlow. Genomics Collaborative was acquired by BioServe Biotechnologies Ltd., a SUB of ReproCELL, Inc. from SeraCare Life Sciences, Inc. on May 29, 2007 for $2 million. | Comptroller/Controller/Auditor | - |
Aeris Therapeutics LLC
Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Financieel Directeur/CFO | - |
Opleiding van Andrew Littlehale
Suffolk University | Masters Business Admin |
Wheaton College (Illinois) | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
SeraCare Life Sciences, Inc.
SeraCare Life Sciences, Inc. Medical SpecialtiesHealth Technology SeraCare Life Sciences, Inc. provides in vitro diagnostics and clinical laboratory products. It supplies diagnostic quality controls, biological materials, and reagents to in vitro diagnostics developers, clinical laboratories, and life science researchers. The firm’s products include Next-Gen Sequencing and Digital PCR Tools, Controls and Reference Materials, Validation and Lot Qualification Materials, Plasma and Serum Diluents/Derivatives, Cell Culture Reagents, KPL Antibodies and Conjugates and KPL Immunoassay Reagents and Kits. The company was founded in 1984 and is headquartered in Milford, MA. | Health Technology |
Aeris Therapeutics LLC
Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Health Technology |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
Genomics Collaborative, Inc.
Genomics Collaborative, Inc. Medical SpecialtiesHealth Technology Genomics Collaborative, Inc. provides clinical samples and applies human genetics to target validation for drug discovery. The company is based in Cambridge, MA. The company was founded by Phyllis I. Gardner and Edward E. Harlow. Genomics Collaborative was acquired by BioServe Biotechnologies Ltd., a SUB of ReproCELL, Inc. from SeraCare Life Sciences, Inc. on May 29, 2007 for $2 million. | Health Technology |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |